The American journal on addictions · 2025
Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soyka Michael, Koller Gabi, Hans-Ulrich Wittchen, Bühringer Gerhard
Аннотация
BACKGROUND AND OBJECTIVES: There are hardly any data from longitudinal studies on the prevalence of mental health disorders in patients in opioid agonist therapy (OAT).
METHODS: Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).
RESULTS: The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).
CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.
METHODS: Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).
RESULTS: The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).
CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.